MAM
RARE icon

Meeder Asset Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Meeder Asset Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-106
Closed -$3.85K – 918
2025
Q2 		$3.85K Buy
+106
New +$3.82K ﹤0.01% 747
2024
Q3 		– Sell
-90
Closed -$3.7K – 933
2024
Q2 		$3.7K Buy
90
+3
+3% +$128 ﹤0.01% 808
2024
Q1 		$4.06K Buy
+87
New +$4.1K ﹤0.01% 654
2022
Q2 		– Sell
-149
Closed -$11K – 2373
2022
Q1 		$11K Sell
149
-1,158
-89% -$80.6K ﹤0.01% 1519
2021
Q4 		$110K Sell
1,307
-1,316
-50% -$107K 0.01% 390
2021
Q3 		$236K Buy
2,623
+943
+56% +$85.2K 0.01% 673
2021
Q2 		$160K Sell
1,680
-299
-15% -$31.2K 0.01% 786
2021
Q1 		$225K Buy
+1,979
New +$269K 0.01% 695
2020
Q4 		– Sell
-3,098
Closed -$254K – 2145
2020
Q3 		$254K Buy
3,098
+2,125
+218% +$176K 0.02% 548
2020
Q2 		$77K Buy
973
+868
+827% +$57.5K 0.01% 821
2020
Q1 		$5K Buy
+105
New +$5.45K ﹤0.01% 1799
2019
Q4 		– Sell
-124
Closed -$5K – 2382
2019
Q3 		$5K Buy
+124
New +$6.74K ﹤0.01% 1770
2019
Q2 		– Sell
-598
Closed -$41K – 2123
2019
Q1 		$41K Buy
598
+456
+321% +$26.1K ﹤0.01% 919
2018
Q4 		$6K Buy
+142
New +$7.76K ﹤0.01% 1378
2018
Q1 		– Sell
-74
Closed -$3K – 1713
2017
Q4 		$3K Buy
+74
New +$3.63K ﹤0.01% 1437
2017
Q3 		– Sell
-99
Closed -$6K – 1735
2017
Q2 		$6K Buy
+99
New +$5.96K ﹤0.01% 1151

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Meeder Asset Management's RARE Position: Q3 2025 in Review

Meeder Asset Management sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2025, closing a stake of 106 shares — an estimated $3.85K sold.

Meeder Asset Management first reported a position in RARE in Q2 2017 and held it in 16 quarters. The position peaked at $254K in Q3 2020. 303 funds tracked by Wall St. Rank hold RARE as of Q3 2025.

  • Meeder Asset Management reported no remaining Ultragenyx Pharmaceutical position as of Q3 2025 after selling out during the quarter.
  • Meeder Asset Management sold 106 Ultragenyx Pharmaceutical shares in Q3 2025, an estimated $3.85K.
  • Meeder Asset Management first reported a position in Ultragenyx Pharmaceutical in Q2 2017 and held it in 16 quarters.
  • Meeder Asset Management's Ultragenyx Pharmaceutical position peaked at $254K in Q3 2020.
  • 303 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2025.

Based on Meeder Asset Management's 13F filing for Q3 2025, filed 24 Oct 2025.